Reviewing Soligenix (NASDAQ:SNGX) and Tonix Pharmaceuticals (NASDAQ:TNXP)

Soligenix (NASDAQ:SNGX – Get Free Report) and Tonix Pharmaceuticals (NASDAQ:TNXP – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

Profitability

This table compares Soligenix and Tonix Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Soligenix N/A -165.32% -97.40%
Tonix Pharmaceuticals -420.45% -80.97% -70.18%

Earnings and Valuation

This table compares Soligenix and Tonix Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Soligenix N/A N/A -$11.08 million ($0.45) -0.49
Tonix Pharmaceuticals $13.11 million 3.53 -$124.02 million ($12.24) -0.19

Soligenix has higher earnings, but lower revenue than Tonix Pharmaceuticals. Soligenix is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Soligenix has a beta of 2.04, suggesting that its stock price is 104% more volatile than the S&P 500. Comparatively, Tonix Pharmaceuticals has a beta of 1.9, suggesting that its stock price is 90% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Soligenix and Tonix Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Soligenix 1 0 0 0 1.00
Tonix Pharmaceuticals 1 0 1 2 3.00

Tonix Pharmaceuticals has a consensus target price of $22.33, indicating a potential upside of 838.38%. Given Tonix Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Tonix Pharmaceuticals is more favorable than Soligenix.

Insider & Institutional Ownership

3.6% of Soligenix shares are owned by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. 1.9% of Soligenix shares are owned by insiders. Comparatively, 2.0% of Tonix Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Tonix Pharmaceuticals beats Soligenix on 10 of the 14 factors compared between the two stocks.

About Soligenix

(Get Free Report)

Soligenix, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare diseases and other serious medical conditions. Its work spans therapeutic programs for inflammatory and immunological disorders, as well as vaccine and medical countermeasure development. The company’s BioTherapeutics programs include HyBryte (SGX301), a topical treatment based on synthetic hypericin being developed for cutaneous T-cell lymphoma, and dusquetide (SGX942), which has been studied for oral mucositis associated with cancer treatment.

About Tonix Pharmaceuticals

(Get Free Report)

Tonix Pharmaceuticals Holding Corp. is a U.S.-based biopharmaceutical company that develops and commercializes medicines for central nervous system disorders and pursues research programs in immunology, rare diseases and infectious diseases. Its product Tonmya (cyclobenzaprine hydrochloride sublingual tablets) received U.S. Food and Drug Administration approval in 2025 for the treatment of fibromyalgia in adults. The company also has a development pipeline that includes drug candidates and vaccine programs, including research targeting smallpox and mpox.

Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.